Now accepting applications for the 2024 Advocacy Navigator program
Advocacy Navigator program accepting applications
Dear Advocate,
Following a successful 2023 program, AVAC is delighted to launch the 2024 Advocacy Navigator program and invites applications from emerging advocates from Eastern and Southern Africa interested in strengthening their skills in HIV prevention advocacy. Applications for the Advocacy Navigator program are now being accepted through 8 March 2024.
The Advocacy Navigator combines training and mentorship for young and emerging advocates in the field of HIV prevention advocacy. The program brings together a small group of individuals for online knowledge- and skills-sharing sessions and pairs them with a mentor from AVAC’s alumni Fellows’ network to apply their learning to a community advocacy project. The program begins with three months of coursework and project development, followed by three months of implementation, when advocates work on their plans.
Twelve advocates from nine countries across Africa completed the Advocacy Navigator program in 2023. Their community projects ranged from advocacy for the introduction of and access to new prevention methods including the dapivirine vaginal ring and injectable PrEP, to the need for more available data for key populations, to a call for expanding choice in HIV prevention. Read testimonials from their experience here.
“It’s not a one-size-fits-all approach; rather, it’s about recognizing the diversity of needs and implementing interventions that truly make a difference. It’s been eye-opening to witness how empowering individuals with the knowledge and skills to advocate for their rights and educate their peers can be a catalyst for change. This project has instilled in me the belief that advocacy is not just about speaking up; it’s about equipping those affected by an issue with the tools they need to be the agents of change themselves.”
Since launching the AVAC Fellows program in 2009, AVAC has recognized the imperative to invest in mobilizing a growing cadre of HIV prevention advocates. The Advocacy Navigator program is leveraging the strength of this extraordinary alumni community to sustainably expand this model through a short online learning and mentorship program to a larger number of people.
Launched in 2017, COMPASS Africa is a civil society coalition with 29 organizations working in three countries as well as regionally and globally, using data-driven advocacy to improve the HIV response with high-impact campaigns. Its achievements to date have set new standards for mobilization and advocacy, improving laws and policies, increasing investment in programs, elevating the leadership of affected communities in the HIV response, and holding all stakeholders to account for targets, commitments and impact.
In December 2023, Pangaea Zimbabwe signed a new two-year, $4.9 million grant agreement with the Bill & Melinda Gates Foundation as the new secretariat of COMPASS Africa. For the first 6 years, AVAC served in this role, and worked with a coalition-wide governance committee to develop a clear transition plan for COMPASS to be led by African civil society organizations.
“Since 2017, we’ve been breaking new ground under COMPASS Africa. We’ve expanded our networks and brought together the superpowers of new and seasoned advocates who have diverse strengths and have joined together to develop and share technical expertise and winning strategies,” said Imelda Mahaka, executive director of Pangaea Zimbabwe. “This is a foundation of collaboration, knowledge-exchange and trust that can and will accelerate innovative advocacy under African leadership. We are so proud to take this step with AVAC and with support and collaboration of the entire consortium.”
COMPASS Africa supports coalitions and organizations based in Malawi, Tanzania, the United States and Zimbabwe, and COMPASS Africa members are currently leading more than two dozen active campaigns to advance HIV prevention and treatment.
“From its founding, COMPASS Africa pursued a vision of collective power and shared decision-making that planned for a future in which an African-based organization would assume leadership as a vital step to sustaining this essential work,” said Mitchell Warren, executive director of AVAC. “The communities who are most affected by HIV uniquely understand their context, challenges and opportunities—their leadership is essential to developing solutions that work. With inclusive governance structures formalized, including Pangaea Zimbabwe as the new secretariat, that leadership is in place, and we are excited that AVAC will continue to be part of the coalition in its new form.”
“As planned from the inception of COMPASS Africa, coalition members are taking their highly successful model to the next level. We are jointly investing in the long-term success of African leadership because it is absolutely essential to breaking cycles that perpetuate inequity and that stall progress in the HIV response,” said Justine MacWilliam, senior program manager and COMPASS Africa partner at AVAC.
Along with the handover of the secretariat from AVAC to Pangaea Zimbabwe, COMPASS Africa has developed a new governance manual strengthening operating structures for the growing coalition. AVAC will continue as a COMPASS Africa sub-grantee and technical partner focused on advocacy strategy and tactics, including ensuring community priorities are influencing global-level HIV policies, funders and programs.
“This effort put a premium on creating structures to deepen and sustain transparency, accountability, effectiveness and continuing growth within the coalition. COMPASS has a track record of remarkable achievements, this new leadership structure ensures we leverage lessons learned, scale up our advocacy, strengthen each other, and set ambitious goals for impacting the HIV response,” said Dr. Lilian Benjamin Mwakyosi, executive director of DARE Organization in United Republic of Tanzania and co-chair of the COMPASS Governance Working Group.
COMPASS Africa has been unparalleled in testing and succeeding with new models for transnational collaboration. The results have brought campaign after campaign that have marshalled the power of data-driven advocacy to advance community priorities and have convinced policymakers to do the right thing. With these latest innovations, COMPASS Africa is now pioneering a leadership structure that offers the field a sustainable model for decolonizing global health.
New Resources to Support Understanding of Scientific Research
We are delighted to share our new Translation Index, a resource for journalists and advocates, to help bridge the gap between scientific research and community understanding. The Translation Index offers health journalists and advocates accurate translations of commonly used and essential scientific and medical terms in 10 African languages.
Journalists and community health workers are often at the forefront of helping people understand complicated science and health terms in their own languages. Providing information in the language it will be reported minimizes errors and helps journalists reach a wider audience. AVAC is grateful for the Sabin Vaccine Institute‘s support in the development of the Translation Index.
“Since many journalists in community radios may not be highly specialized, the translation of technical science terms into vernacular languages is essential for audience comprehension. This becomes particularly relevant during crises, as witnessed during the pandemic when different radio stations provided varying names for COVID-19 in the same language.”
Since 2012, AVAC has collaborated with health journalist associations in East and Southern Africa through its Media Science Café Program to strengthen the capacity of journalists to report on HIV prevention research. In 2020, AVAC and partners expanded this work to include COVID-19 science. Today, AVAC partners with health media associations in Kenya, Malawi, Tanzania, Uganda, Zambia and Zimbabwe to bring journalists together with researchers, implementers, civil society, policy makers, regulators and policy makers to build relationships that will foster accurate reporting of HIV, COVID-19 and other science or health stories in those countries.
“Having a platform in Malawi for communicating science in local languages is a great innovation that will also enable more of the population to be able to follow science, research and other innovation in global and public health from a scientific perspective and participate in the discourse.”
– Dingaan Mithi, journalist and JournAIDS program manager
We hope you will visit the Translation Index and join us on the 23rd.
The Search for an HIV Vaccine Must Continue
Field Will Learn for Halted PrEPVacc Arm
By Jeanne Baron
Today the PrEPVacc trial team announced at a special session at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe, that they were stopping vaccinations in the study following a review by an independent data safety committee that determined there was little chance the vaccines being tested could stop HIV acquisition. The oral PrEP arms of the study will continue.
PrEPVacc was testing two different vaccine strategies against a placebo: one regimen combining a DNA vaccine with a protein-based vaccine (AIDSVAX), and another regimen combining DNA, MVA and a protein-based vaccine (CN54gp140).
“We always hope for a positive outcome in HIV prevention trials, and this news is disappointing,” said Mitchell Warren, AVAC executive director. “We look forward to seeing the full PrEPVacc data in 2024 and hope it will add to the body of evidence that is helping scientists understand how to develop better vaccine candidates that will one day protect against HIV.”
“The PrEPVacc outcome underscores yet again that the science of HIV vaccine development is extremely challenging,” he added. “Now is not the time to step back from vaccine research. There are several promising strategies in early-stage research that must continue, along with research for other HIV prevention options. We will not end HIV without ensuring that everyone who is vulnerable to HIV infection has a choice of effective and desirable prevention options.”
Importantly, PrEPVacc’s PrEP arms will continue. The study is testing two different formulations of daily oral PrEP, looking to see if a new formulation – F/TAF (also known as Descovy) – is at least as good in the trial population at protecting against HIV acquisition as F/TDF (also known as Truvada and the most widely used version of PrEP). The trial will provide the first data for F/TAF among cisgender women (who make up 87% of the just over 1,500 PrEPVacc trial participants). F/TAF is approved for use in the US and UK, but not for those individuals who have receptive vaginal sex, since previous trials regrettably did not enroll cisgender women.
The PrEPVacc study is scheduled to conclude in 2024 and data from all arms of the study are expected to be reported in the last half of 2024.
“The PrEP arms of PrEPVacc will provide important insights into the potential of expanding access of F/TAF for PrEP to women in East and Southern Africa who need additional options to protect themselves from HIV. Equitable access to new interventions should be a goal of every research program,” said Stacey Hannah, AVAC’s director of Research Engagement.
“PrEPVacc is a complex, innovative trial design, and, while the vaccine result today is disappointing, the trial team has worked from the outset to implement the Good Participatory Practice (GPP) Guidelines. The team’s hard work on the front-end to apply GPP to this trial is paying off especially now in the ability to deliver complex, disappointing results to trial participants, advocates, policymakers and other key supporters of PrEPVacc and of HIV prevention broadly.”
ICASA 2023: Demands for equity and investment in the HIV response
By Jeanne Baron
At the ongoing International Conference on AIDS and STIs in Africa (ICASA), the struggle to sustain an evidence- and rights-based HIV response is heating up. HIV prevention and global health equity depend on continuing to build on the gains to date, to learn from mistakes, and to invest in scaling up now-proven solutions while developing additional ones. But all these principles are increasingly threatened by political reaction and short-sighted investment. AVAC and partners released four major calls to action at ICASA to confront these urgent challenges, which are imperiling the communities most burdened by HIV and other health inequities. Each of these resources set an agenda to address critical gaps.
A permitted People’s March scheduled for December 5 in Harare was cancelled due to acute safety concerns following the arrest of conference attendees at a demonstration, and other intimidating police actions against civil society and key populations at the conference. AVAC is part of coalition that issued an open letter to the conference secretariat condemning the suppression of community voices and calling for the People’s March to go forward and future guarantees that ICASA host countries commit to allowing community voices to be heard and ensuring their activities are unhindered.
This roadmap outlines a strategy for the equitable expansion and delivery of HIV prevention services to key populations (KPs) globally and regionally. It introduces a critical, coordinated approach led by KPs to accelerate the implementation of existing and new HIV prevention interventions. Developed by the Global KP HIV Prevention Advisory Group (KPAG) and allied stakeholders, this roadmap represents near-term priorities for funding, U=U, PrEP targets, the advancement of rights— particularly decriminalization of key populations and more for key stakeholders and regions to achieve by mid 2025. This roadmap is a terrific complement to the recently-released Choice Manifesto, led by women advocates throughout Eastern and Southern Africa.
“This is nothing new, we’ve been saying this for years, but now it is more urgent than ever: Funding to key populations must go beyond services to support our advocacy and our activism. Decriminalization is imperative. We are not criminals, and with a stroke of the pen decriminalizing key populations could lead to lower incidence of HIV,” said KPAG member and former AVAC Fellow, Josephine Aseme at a press conference promoting the importance of this roadmap.
Faith leaders from across the region convened by African Services Committee, AVAC, GALZ & Inerela joined in solidarity in defense of human rights and evidence-based HIV prevention, including for vulnerable populations. Among the pledges, participating faith leaders are committing to engage in cultural and legislative initiatives related to LGBTQIA+ issues that promote love, grace, compassion, equity and justice for all.
“VMMC offers us an exceptional opportunity to get men into the healthcare system but we have gone off track. We can’t afford to lose momentum. The job is not yet done. New funding is needed now. Integration is needed now. Sustained commitment is needed now.” – Chilufya Kasanda Hampongo, TALC Zambi
All four initiatives launched at ICASA take aim at critical gaps in the HIV response. Each provide resources that outline next steps and roles for stakeholders across the field to advance equity, and in turn help the world reach global targets to end the epidemic.
AVAC Commemorates World AIDS Day
This World AIDS Day we at AVAC are reflecting on remarkable gains and increasing threats to progress against AIDS. Our latest issue of PxWire, tracking trends in research, development and delivery of HIV prevention options, speaks to this important progress:
Five countries have reached the UNAIDS 95-95-95 targets with more than 29 million people accessing treatment, and global incidence continuing to decline – in some places, among some populations.
However, as we look to 2024, all these gains could be imperiled by political and financial choices facing leaders today.
Will the US Congress recognize the unparalleled success of PEPFAR and safeguard its funding through a clean 5-year reauthorization?
Will health officials and policy makers embrace the Choice Manifesto, created by HIV advocates and adopted by UNAIDS Executive Director Winnie Byanyima, calling for the essential investments that will bring these diverse options to the communities that need them most?
The answers to these questions will require donors and political leaders to do the right thing, and it will depend on us, a global movement of advocates with a track record of world-changing achievements, to stay the course and build the road to reach everyone one of these goals. Below are a few key resources to support your work.
From the Lab to the Jab
A series of advocates guides on key issues to ensure equitable access to safe, effective, and affordable vaccines.
POZ Magazine’s interview with Mitchell Warren, with a comprehensive look at the status of the fight against HIV/AIDS and the scientific breakthroughs to date and still needed to end the epidemic.
A Call to Action: Scale Up HPV Vaccination in People Living with HIV
In a new call to action, Mitchell Warren and Heather White, executive director of TogetHER for Health, argue that the time is now to invest in efforts to ensure that people living with HIV can live their lives without the threat of cervical cancer.
At AVAC, we believe it’s up to all of us to make sure the world does not squander another decade in slow, fragmented rollout of life-saving innovation in HIV prevention or risk underfunding research and development. If we work together to build equity into the rollout of options that exist already and support the promise of expanding choices in the near future, the world will at long last bend the curve of HIV.
Scale Up HPV Vaccination in People Living With HIV
A Call to Action
By Mitchell Warren, Executive Director of AVAC, and Heather White, Executive Director of TogetHER for Health. This post first appeared at togetherforhealth.org.
HIV/AIDS and cervical cancer are two global health emergencies that impact millions around the world – and unfortunately, the relationship does not end there. The dire synergy between HIV/AIDS and cervical cancer can be expressed in some startling statistics:
Cervical cancer is on the relatively short list of “AIDS-defining illnesses”—cancers and opportunistic infections that can be life-threatening to people living with HIV.
Women living with HIV are up to six timesmore likely to develop invasive cervical cancer than their HIV-negative peers.
Women testing positive for infection with the human papillomavirus (HPV) that causes almost all cervical cancers are twice as likely to be infected with HIV.
The proportion of cervical cancer cases attributable to HIV is greater than 40% among the eight countries with highest HIV prevalence in sub-Saharan Africa, compared to less than 5% in 127 countries with lower HIV prevalence, highlighting major disparities in the global burden.
Additionally, HIV/AIDS and cervical cancer share many barriers to effective prevention, treatment, and care. Efforts to provide services to address both diseases are beset with social stigma and misinformation.
Due to their elevated risk of disease, women living with HIV, and those at risk of HIV are considered priority populations for cervical screening. The US President’s Emergency Plan for AIDS Relief (PEPFAR)invests more in cervical cancer screening and treatment in low- and lower middle-income countries than any other funder. The Global Fund to Fight AIDS, TB, and Malaria will also fund requests for cervical cancer prevention aligning with HIV prevention programs. The SUCCESS collaborationfunded through Unitaid and implemented by Expertise France, Jhpiego, and the Union for International Cancer Control (UICC) is introducing and promoting the best available screen-and-treat tools to prevent cancer in women most at risk, especially those living with HIV.
But these lifesaving efforts are only reaching a fraction of those in need.
While efforts to develop a preventive vaccine against HIV are underway, vaccines against HPV have proven to be safe and effective for people already living with HIV—greatly reducing their chance of developing cervical cancer. Given their enhanced likelihood of developing cervical cancer, it is critical to focus additional attention on vaccinating people living with HIV, as well as young people vulnerable to both HIV and HPV infections. Unfortunately, few targeted efforts to ensure widescale uptake of HPV vaccination in people living with HIV have been made.
According to data from the World Health Organization (WHO), only around 25 percent of women living in the Africa Region – the region with the highest burden of HIV/AIDS—are currently vaccinated against HPV. Current WHO guidance recommends at least two doses of HPV vaccine for people living with HIV, requiring not just effective implementation of initial vaccination but also efforts to ensure subsequent follow-up to complete the recommended regimen. A lack of disaggregated data on the proportion of people living with HIV who remain unvaccinated against HPV hampers the creation and implementation of targeted HPV vaccination strategies in populations with increased chance of acquiring HIV.
It’s well past time to build an evidence-based plan to ensure access to critical comprehensive health services for adolescent girls and young women at risk for HIV, or those living with the disease, using a lifecourse approach. Specifically, to improve coverage of HPV vaccination, we call on global bodies to take urgent steps to:
Assess the current status of HPV vaccination among girls and women living with HIV. A dearth of reliable global and regional data must be addressed if we are to ensure wider uptake of HPV vaccination in populations of people living with HIV. Effective monitoring of is a critical first step toward addressing the gap in HPV vaccination coverage for people living with HIV.
Create evidence-based HPV vaccination strategies for people living with HIV. Programs should take advantage of opportunities to integrate HPV vaccination alongside HIV prevention, treatment, and care services, alongside outreach and awareness activities to break down stigma and combat misinformation.
Build the evidence base supporting HPV dosing schedules for people living with HIV. Current WHO guidance has shifted to a single-dose regimen for HIV-negative populations. Clinical research can affirm the need for multi-dose regimens for people living with HIV, but may also support a shift to single-dose schedules that can ensure wider access to more individuals.
This call to action couldn’t be more timely, as one lingering constraint to accelerating access to HPV vaccination for people living with HIV—limited vaccine supply—is expected to be all but removed in the near future. UNICEF projects that by 2024 the supply of HPV vaccines will for the first time align with the demands of the programs UNICEF services, most notably Gavi, the Vaccine Alliance, the most prominent implementer of HPV vaccination services in low- and lower middle-income countries. Gavi’s ambitious goal of vaccinating 86 million adolescent girls in its focus countries against HPV by 2025 presents a unique opportunity to close a vaccination gap in people living with HIV.
Today – December 1st – is World AIDS Day. Two weeks ago on November 17th, the world marked the third annual Cervical Cancer Elimination Day of Action. The proximity of these two days of advocacy provides an opportunity to highlight another connection shared by HIV/AIDS and cervical cancer: the opportunity to invest to end these dual health threats by scaling up effective services and meeting global targets – the 95-95-95 HIV treatment goals set by UNAIDS and the 90-70-90 cervical cancer preventiongoals set forth by WHO.
UNAIDS’ Global AIDS Strategy incorporates sub-goals for women and girls vulnerable to developing cervical cancer, representing a confluence of these two remarkable global health endeavors. The Strategy calls for:
90 percent of girls aged 9–14 in priority countries gaining access to HPV vaccination;
90 percent of women living with HIV being provided access to integrated or linked services for HIV treatment and cervical cancer; and
90 percent of women, adolescent girls and young women accessing sexual and reproductive health services, including for HPV and cervical cancer, that integrate HIV prevention, testing and treatment services.
The alignment of HIV/AIDS and cervical cancer targets reflects an evidence-based understanding that ending preventable deaths from these two diseases is best done in tandem.
We know that effective plans supported by sufficient political and financial support can achieve these goals—saving millions of lives. The time to invest to ensure that people living with HIV can live their lives without the threat of cervical cancer is now.
AVAC and Partners at ICASA 2023
Join AVAC and partners for the biennial International Conference on AIDS and Sexually Transmitted Infections (ICASA), in Harare, Zimbabwe December 4-9. More than 30 of our partners will convene at the meeting to champion community leadership and amplify their role in shaping local, national and global responses and delivering impactful advocacy. Community leadership on a range of issues are instrumental to:
Accelerate and expand access to proven prevention options that people want and need.
Dismantle the structural barriers to health faced by key populations.
Intensify demands for robust domestic and global funding for health.
Integrate HIV services with sexual and reproductive health.
And much more.
Scroll down for a roadmap to ICASA’s prevention program, and details on sessions and events that you won’t want to miss.
Biomedical Prevention Forum 9:00-15:00 GMT The Biomedical Prevention Forum will be held as a hybrid event bringing together advocates, civil society representatives, researchers, government officials and front-line providers to explore and discuss the latest advancements, challenges, and opportunities in biomedical HIV prevention, while emphasizing the importance of choice and its transformative impact on HIV prevention efforts. This is an open event. Register here.
Key Populations Preconference 9:00-15:00 GMT The Africa Key Populations Experts Group (AKPEG), African Sex Workers Alliance (ASWA), the African Network of People Using Drugs (AfricanPUD) and African Queer Youth Initiative (AQYI) Advocates for Prevention of HIV and AIDS in Africa (APHA), Global Black Gay Men Connect (GBGMC) and partners will host a safe platform to deliberate on the state of the HIV epidemic among Key Populations and to determine the stumbling blocks for progress on the path that ends AIDS for Key Populations.
Shaping the future of choice in prevention: Gearing up for the rollout of the Dual Prevention Pill, the newest MPT in the toolbox 12:25-13:10 GMT The Dual Prevention Pill (DPP), a daily pill combining oral PrEP and combined hormonal oral contraception for dual pregnancy and HIV prevention, could be introduced in the next two years and would be the only other MPT available in addition to male and female condoms – and the first MPT containing PrEP. This session will discuss the latest learnings from the DPP Consortium, a coalition of organizations preparing for the introduction of the DPP in Zimbabwe, South Africa and Kenya.
Tuesday, December 5
Advancing Integrated Biomedical Prevention: Best Practices from Zimbabwe (Session 2) 8:45-09:30 GMT This satellite session will discuss best practices and lessons learned from the delivery of biomedical HIV prevention and Voluntary Medical Male Circumcision services as we work to further universal health coverage and robust health systems. Partners will launch a global call to action to unite, mobilize, and advocate for continued prioritized funding, sustained commitment, and strategic integration of VMMC into national and global prevention strategies.
Catalyzing a sustainable HIV prevention agenda: Approaches to expand local action on global commitments 10:45-11:30 GMT Leveraging new strategic plans for HIV prevention, including the PEPFAR’s 5-year Strategy and UNAIDS’ Prevention Road Map, this satellite session will discuss combination prevention in the context of a sustainable HIV response and highlight a variety of approaches and models that leverage country and stakeholder-led innovations to meet the challenge.
Policy, Politics and HIV Management 13:05-13:50 GMT In this oral abstract session, Princess Mharire from Pangaea Zimbabwe AIDS Trust (PZAT) will present, Beyond Metrics: How the Simple Participatory Assessment of Real Change (SPARC) Tool Provides a Holistic Approach to Advocacy Measurement, and Joseph Njowa of PZAT will share the COMPASS MERL model in a presentation, Innovative tools for planning, monitoring, and evaluation of advocacy campaigns.
Strengthen integration for better SRHR outcomes 10:45-11:30 GMT This concurrent session will feature Advocates for Prevention of HIV and AIDS in Africa’s (APHA) Yvette Raphael and will explore linkages between unintended pregnancies, unsafe abortion, and HIV.
HIV Prevention-Right Place, Right time 13:05-13:50 GMT This concurrent session will feature Maureen Luba of AVAC, Definate Nhamo of PZAT and Yvette Raphael of APHA.
AVAC and Partner Poster Presentations
Tuesday, December 5
Maximizing private pharmacies for PrEP delivery to increase uptake: Lessons learnt from the Community Retail Pharmacy Distribution Point, Ruth Akulu
Wednesday, December 6
Journalist Training: A Key Advocacy Strategy, Catherine Madebe
Perceptions on the new biomedical HIV prevention methods among adolescent girls and young women in tertiary institutions in Zimbabwe, Cleo Makura
Lessons from Crisis Response from TaNPUD in Enhancing Harm Reduction from 2015 to 2018, Marineus Mutongore
Implementing Community led Monitoring for improved quality of HIV services in Tanzania, Mathew Kawogo
Impact of social media exposure on HIV services uptake among Tanzanian Young people: Implications for enhancing the HIV response, Marineus Mutongore
Effective Strategies for Operating COWLHA support groups of Adolescents Living with HIV: Case of Mangochi and Chikwawa Districts of Malawi, Harry Madukani
Thursday, December 7
Understanding Choice of HIV Prevention Options among Adolescent Girls and Young Women (AGYW) in Zambia, Natasha Mwila
Leveraging HIV to Build a Global Health Research and Development (R&D) Equity Advocacy Agenda, John Meade
Championing advocacy for domestic resource mobilization for health research and development in Africa, Ethel Makila
Friday, December 8
Rural Youth: Underserved and Unsafe When Seeking Care, Liyema Somnono
Redefining Coalition Governance and Leadership in Support of Decolonizing Global Health: The Evolution of the COMPASS Coalition, Roberta Sutton
Collaborative Monitoring & Evaluation to Support Learning and Strengthen Advocacy Coalitions: The MERL Hub, Grace Tetteh
Realities faced by street children predisposing them to HIV and STIs in Dodoma and Dar es Salaam Cities in Tanzania, Simon Shilagwa
New Issue of PxWire: The latest in HIV prevention R&D and Delivery
As we look back on 2023, powerful cross currents confront HIV prevention and global health equity. More options than ever before could be available, but many forces threaten to undermine access to proven prevention options that exist today and the development of additional options that are still needed. Threats to PEPFAR and hate laws targeting LBGTQI+ people are just a sample.
Upstream research and development is dynamic, but robust stakeholder engagement and sustainable funding must still be secured and integrated into a people-centered research agenda. These commitments are the compass that will ultimately lead to impact in the real world. The highlights in the latest issue of PxWire provide a snapshot of key updates in Q3 of 2023 and resources to inform advocacy on these critical questions.
On This #GivingTuesday Support Community Leadership in HIV Prevention
Today, UNAIDS released its World AIDS Day report, Let Communities Lead. This year’s focus on community leadership is especially important to all of us at AVAC as it lies at the heart of our work for our entire 28-year history. The UNAIDS report highlights what we and our partners have raised over the years—that communities face enormous barriers, community-led responses are under-recognized, under-resourced and in so many ways, under attack.
From our almost 30 years of experience in HIV prevention advocacy, it’s clear that working in solidarity with communities is imperative to address the root causes of inequity. Community-led responses are essential components of the comprehensive approach needed to end the epidemic.
At AVAC, we are incredibly proud of our history and in our collaborative work in 2023 to champion civil society and community leadership in shaping local, national and global responses.
Today, as part of #GivingTuesday, a global day dedicated to giving back, we ask you to consider supporting AVAC so that we and our partners can continue to deliver the effective and impactful advocacy that is described below—and is needed now more than ever.
Your support to AVAC now will ensure that we and our partners can continue putting people and communities at the center of our work, ensuring that the global response is connected to the real needs of affected people.
Advancing bold and innovative agendas for HIV prevention.
In September, the African Women’s HIV Prevention Community Accountability Board (AWCAB) launched its HIV Prevention Choice Manifesto in Kampala, Uganda. The manifesto represents a historic milestone in the power of community leadership to re-frame the global discussion around community priorities. The manifesto calls for political will and financial investment to ensure access to the prevention options that women and girls in Africa say that they want. AVAC worked closely with partners to establish this coalition and catalyze its advocacy.
Supporting communities to engage in the science of HIV and process of R&D.
The Good Participatory Practice (GPP) guidelines co-developed by AVAC and UNAIDS nearly 15 years ago have become a field-wide standard for broad and inclusive stakeholder engagement in clinical trial research. At AVAC, we train trial staff on the guidelines, support their adaptation to other fields, prepare and support advocates in applying GPP in trial communities, and engage with the research community and ethics boards to maximize their use. Our new GPP Body of Evidence, takes this a step further, offering GPP resources to advocates that demonstrate its power, show how it can be measured and replicated, and provide GPP training, tools and connection to everyone involved in the research enterprise.
Improving how, when and to whom prevention is delivered.
Developing—and delivering—a rich pipeline of options for HIV prevention must be guided by community priorities that define what products are needed and how they are delivered for impact. In a new opinion editorial published today in South Africa’s Bhekisisa, AVAC’s Wawira Nyagah and Mitchell Warren lay out essential lessons to ensure that a broad range of prevention options that people want and need are developed, tested and distributed equitably, at scale and with urgency. “The world cannot afford to squander another decade through slow, fragmented rollout of life-saving HIV prevention. With longer-lasting options now becoming available… the world could finally bend the curve of HIV—but only if investment and planning for delivery are as evidence-based, person-centered and innovative as research and development in new products.”
Supporting a robust partner network that puts prevention on national and global agendas.
Effective coordination and balanced partnerships are key to creating a policy environment, accelerating ethical product development and advocating for equitable access to emerging health solutions. AVAC partners with a global movement of advocates to bring community voices, sustained attention and greater accountability to science, policy, funding, media, health services and regulatory processes. We are proud of the skills and power-sharing and impact-oriented advocacy that has expanded and refined prevention targets, accelerated development of guidelines and reshaped policies and programs through our long-standing Advocacy Fellows program, the Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS) Africa and the Coalition to Accelerate and Support Prevention Research (CASPR).
Fighting to keep community priorities at the center of global health.
The Coalition of Advocates for Global Health and Pandemic Preparedness is tracking the issues, keeping civil society informed, and developing tools and resources. These efforts are essential to advocacy for an integrated and holistic approach to pandemic preparedness, which depends on safeguarding equity and building on the success of the HIV response. As founding members of the coalition, we’ve been proud to fight for community priorities in the work of ACT-A, the Pandemic Fund, the Pandemic Accord, the UN High Level Meeting on PPPR, and the development of a medical countermeasures platform. AVAC published the Advocates Guide for PPPR in 2023 as a go-to resource on the issues.
It is a privilege to do the work that we do. Without communities pointing the way, the HIV response will flounder, and global health will go backwards. The strength and leadership of our partners and the communities in which we work is the foundation of our hope for HIV prevention and for global health equity. We thank you for your support.
Many thanks for your partnership, solidarity and support.
